Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial — Stella

Home/Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)/

View on ClinicalTrials.gov

Recruiting

Back to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

China

Chinese PLA General Hospital, Beijing, Beijing Municipality

Key details

Phase

Post-approval study

Sponsor

Chinese PLA General Hospital

Collaborators

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Peking University People's Hospital

Enrollment target

~200 participants

Started

January 2025

Primary completion

January 2028

Age range

14 Years – 75 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.